# Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma

> **NCT07691450** · PHASE1 · NOT_YET_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 40 (estimated)

## Conditions studied

- Recurrent Anaplastic Large Cell Lymphoma
- Recurrent Enteropathy-Associated T-Cell Lymphoma
- Recurrent Follicular Helper T-Cell Lymphoma
- Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type
- Recurrent Follicular Helper T-Cell Lymphoma, Follicular-Type
- Recurrent Follicular Helper T-Cell Lymphoma, Not Otherwise Specified
- Recurrent Hepatosplenic T-Cell Lymphoma
- Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
- Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Recurrent Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma
- Recurrent Primary Cutaneous Gamma-Delta T-Cell Lymphoma
- Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma
- Refractory Anaplastic Large Cell Lymphoma
- Refractory Enteropathy-Associated T-Cell Lymphoma
- Refractory Follicular Helper T-Cell Lymphoma
- Refractory Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type
- Refractory Follicular Helper T-Cell Lymphoma, Follicular-Type
- Refractory Follicular Helper T-Cell Lymphoma, Not Otherwise Specified
- Refractory Hepatosplenic T-Cell Lymphoma
- Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Refractory Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
- Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Refractory Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma
- Refractory Primary Cutaneous Gamma-Delta T-Cell Lymphoma
- Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Belinostat
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** FDG-Positron Emission Tomography
- **OTHER:** Fludeoxyglucose F-18
- **PROCEDURE:** Positron Emission Tomography
- **DRUG:** Pralatrexate
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT07691450
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-03
- **Primary completion:** 2029-11-24
- **Final completion:** 2029-11-24
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07691450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07691450, "Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07691450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*